Moreover, the phase III ADAURA analysis demonstrated a clinically significant disease‐free survival (DFS) benefit with adjuvant osimertinib versus placebo in EGFR‐mutated stage IB‐IIIA non‐small‐cell lung cancer (NSCLC) after complete tumor resection [45]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.